Kawa Khaled Ajgeiy Selected Research

Therapeutics

11/2023	Drug Survival of Adalimumab, Secukinumab, and Ustekinumab in Psoriasis as Determined by Either Dose Escalation or Drug Discontinuation during the First 3 Years of Treatment - a Nationwide Cohort Study.
1/2021	Response to Biologics During the First Six Months of Therapy in Biologic-naïve Patients with Psoriasis Predicts Risk of Disease Flares: A Danish Nationwide Study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Kawa Khaled Ajgeiy Research Topics

Disease

5	Psoriasis (Pustulosis Palmaris et Plantaris) 11/2023 - 01/2021
2	Angioedema 01/2018 - 01/2017
1	Infections 11/2022
1	Necrosis 10/2021

Drug/Important Bio-Agent (IBA)

2	Adalimumab (Humira)FDA Link 11/2023 - 06/2021
2	secukinumabIBA 11/2023 - 10/2021
2	Ustekinumab (CNTO 1275)FDA Link 11/2023 - 10/2021
2	Interleukin-12 (IL 12)IBA 11/2022 - 10/2021
2	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 01/2018 - 01/2017
1	Immunosuppressive Agents (Immunosuppressants)IBA 11/2022
1	Valacyclovir (Valtrex)FDA LinkGeneric 11/2022
1	Famciclovir (Famvir)FDA LinkGeneric 11/2022
1	Acyclovir (Aciclovir)FDA LinkGeneric 11/2022
1	Methotrexate (Mexate)FDA LinkGeneric 11/2022
1	Interleukin-17 (Interleukin 17)IBA 11/2022
1	Biosimilar PharmaceuticalsIBA 06/2021

Therapy/Procedure

2	Therapeutics 11/2023 - 01/2021
1	Biological Therapy 10/2022
1	Duration of Therapy 10/2022
1	Airway Management 01/2017